Core Insights - Zentek Ltd. is an intellectual property technology development and commercialization company that has provided an update regarding its subsidiary Albany Graphite Corp. on activities funded by the Critical Minerals Innovation Fund [1] Group 1 - The update highlights the progress made by Albany Graphite Corp. in relation to its grant-funded activities [1]

Core Viewpoint - Zentek Ltd. has successfully completed the first in vivo tests of its lead candidate countermeasure for seasonal influenza (H1N1) as part of the Innovative Solutions Canada Testing Stream [1] Company Summary - Zentek Ltd. is listed on Nasdaq under the ticker ZTEK and on TSX-V under the ticker ZEN [1]

Core Points - Zentek Ltd. is updating its slate of director nominees for the upcoming annual general and special meeting scheduled for September 25, 2025 [1] Company Updates - The announcement follows a previous news release dated September 3, 2025, indicating ongoing developments within the company [1]

Core Viewpoint - Zentek Ltd. has successfully closed a non-brokered private placement of debenture units, raising gross proceeds of $2,000,000 through the issuance of 2,000 debenture units [1] Group 1: Offering Details - Each debenture unit consists of $1,000 principal amount of 5% secured convertible debentures and 454 warrants to purchase common shares [2] - The convertible debentures will mature on April 9, 2028, and bear interest at a rate of 5% per annum, payable as a balloon payment on the maturity date [2] - The conversion price for the convertible debentures is set at $2.20 per common share, with the company having the option to force conversion if the trading price exceeds $4.40 [2] Group 2: Security and Warrants - The convertible debentures are secured by the company's interest in 521 mining claims held by its subsidiary Albany Graphite Corp., with a first ranking above all other creditors [3] - A total of 908,000 warrants were issued, each allowing the holder to purchase one common share at the conversion price until the maturity date [4] - The warrants will vest only upon the completion of a sale or transfer of the secured assets to a third party [4] Group 3: Use of Proceeds and Regulatory Approval - Net proceeds from the offering will be utilized for working capital and general corporate purposes [5] - The closing of the offering is subject to necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [5] Group 4: Company Overview - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of novel products [7] - The company's patented technology platform, ZenGUARD™, significantly increases bacterial and viral filtration efficiency for surgical masks and aims to enhance HVAC systems [9]

Core Viewpoint - Zentek Ltd. has announced an at-the-market offering agreement to raise up to US$30 million through the sale of common shares in the United States [1][4]. Group 1: Offering Details - The offering will be conducted through an "at-the-market offering" as defined under U.S. Securities Act, with sales made directly on Nasdaq or other recognized marketplaces [3]. - The offering will remain effective until the total gross sales reach US$30 million, unless terminated earlier by any party involved [4]. - Sales will occur at prevailing market prices, which may vary, and net proceeds will be used for corporate purposes as outlined in the Prospectus Supplement [4]. Group 2: Regulatory and Legal Framework - The common shares will be issued under a prospectus supplement dated March 3, 2025, as part of an existing U.S. registration statement [5]. - The offering is being made solely through the Prospectus Supplement, which has been filed with the SEC [5]. - The press release clarifies that it does not constitute an offer to sell or solicit offers to buy securities in jurisdictions where such actions would be unlawful [6]. Group 3: Company Background - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on developing and commercializing innovative products [7]. - The company’s patented technology platform, ZenGUARD™, enhances viral filtration efficiency for surgical masks and HVAC systems [8]. - Zentek holds a global exclusive license to an Aptamer-based platform technology developed by McMaster University, aimed at diagnostic and therapeutic markets [9].

Core Viewpoint - Zentek has provided an update on its ZenGUARD(TM) enhanced air filters, specifically targeting the Canadian market, highlighting advancements in technology and market strategy [1] Group 1: Product Development - ZenGUARD(TM) air filters utilize a patented technology that enhances air quality by capturing and neutralizing airborne pathogens [1] - The filters are designed to be compatible with existing HVAC systems, making them an attractive option for various commercial and residential applications [1] Group 2: Market Strategy - The company is focusing on expanding its presence in the Canadian market, leveraging partnerships with local distributors to enhance market penetration [1] - Zentek aims to address the growing demand for improved air quality solutions, particularly in light of increased awareness surrounding health and safety in indoor environments [1] Group 3: Financial Implications - The introduction of ZenGUARD(TM) is expected to contribute positively to the company's revenue streams, as the demand for air filtration solutions continues to rise [1] - Zentek is positioning itself to capitalize on government initiatives and funding aimed at improving public health through better air quality [1]

Core Points - Zentek Ltd. announced the voting results from its annual and special meeting of shareholders held on September 26, 2024, with all resolutions being approved by shareholders [3]. - The election results for the board of directors showed high approval rates for all nominees, with Lisa Sim receiving the highest at 98.638% [4]. - Shareholders approved the appointment of BDO Canada LLP as auditors with a significant majority of 99.275% [5]. - The omnibus long-term incentive plan was also approved, receiving 82.077% votes in favor [5]. Company Overview - Zentek Ltd. is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of innovative products aimed at enhancing the competitiveness of its commercial partners [6]. - The company's patented technology platform, ZenGUARD™, demonstrates 99% anti-microbial activity and aims to improve viral filtration efficiency for surgical masks and HVAC systems [7].

● . . Zentek Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency September 13, 2024 4:45 PM EDT | Source: Zentek Ltd. Guelph, Ontario--(Newsfile Corp. - September 13, 2024) - Zentek Ltd. (NASDAQ: ZTEK) (TSXV: ZEN) ("Zentek" or the "Company") announces that on September 11, 2024, it received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of t ...

Core Points - Zentek Ltd. has successfully closed a non-brokered private placement of units, raising gross proceeds of $3,069,950 through the issuance of 2,361,500 units at a price of $1.30 per unit [2][3] - The net proceeds from the offering will be allocated for working capital and general corporate purposes, supporting the company's international market expansion strategy [3][4] - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at a price of $3.00 for a period of 24 months [3][4] Financial Details - The cash commission paid to eligible persons in connection with the offering totaled $29,499.40 [4] - The offering is subject to necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [4] Company Overview - Zentek is an intellectual property development and commercialization company focused on creating novel products that enhance the safety and sustainability of commercial partners' offerings [6] - The company's patented technology platform, ZenGUARD™, demonstrates 99% anti-microbial activity and aims to improve viral filtration efficiency in HVAC systems [7]

Core Points - Zentek Ltd. has announced an upsized non-brokered private placement of units, increasing the offering to 2,361,538 units at a price of $1.30 per unit, resulting in aggregate gross proceeds of up to $3,070,000 [2][3] - The net proceeds from the offering will be allocated for working capital and general corporate purposes [3] - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one common share at a price of $3.00 for a period of 24 months from the closing date [3] Additional Information - The company may pay a cash commission of 5% of the gross proceeds to eligible finders who introduce subscribers to the offering [4] - The closing of the offering is contingent upon receiving all necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [5] - All securities issued will be subject to a hold period of four months plus a day from the date of issuance [5] Company Overview - Zentek Ltd. is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of novel products aimed at providing competitive advantages to commercial partners [7] - The company's patented technology platform, ZenGUARD™, demonstrates 99% anti-microbial activity and aims to enhance viral filtration efficiency for surgical masks and HVAC systems [8]